Literature DB >> 10212557

T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability.

R Joober1, C Benkelfat, K Brisebois, A Toulouse, G Turecki, S Lal, D Bloom, A Labelle, P Lalonde, D Fortin, M Alda, R Palmour, G A Rouleau.   

Abstract

Although genes play a major role in the etiology of schizophrenia, no major genes involved in this disease have been identified. However, several genes with small effect have been reported, though inconsistently, to increase the risk for schizophrenia. Recently, the 5HT2A 2 allele (T102C polymorphism) was reported to be over-represented in patients with schizophrenia. Other reports have found an excess of allele 2(C) only in schizophrenic patients who are resistant to clozapine, not in those who respond to clozapine. In this study, the 5HT2A receptor allele 2 frequencies were compared between 2 groups of patients with schizophrenia (39 responders and 63 nonresponders) based on long-term outcome and response to typical neuroleptics. A control group of 90 healthy volunteers screened for mental disorders was also included. Genotype 2/2 tended to be more frequent in patients with schizophrenia with poor long-term outcome and poor response to typical neuroleptics (Bonferroni corrected p = 0.09). This difference was significant in men (Bonferroni corrected p = 0.054) but not in women. In addition, the age at first contact with psychiatric care was significantly younger in the patients with schizophrenia with genotype 2/2 than in patients with genotype 1/1. These result suggest that the 5HT2A-receptor gene may play a role in a subset of schizophrenia characterized by poor long-term outcome and poor response to neuroleptics.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10212557      PMCID: PMC1188995     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  34 in total

Review 1.  Molecular genetics of hereditary dystonia--mutations in the GTP cyclohydrolase I gene.

Authors:  H Ichinose; T Nagatsu
Journal:  Brain Res Bull       Date:  1997       Impact factor: 4.077

2.  5-HT2 receptor gene locus: association with schizophrenia or treatment response not detected.

Authors:  V L Nimgaonkar; X R Zhang; J S Brar; M DeLeo; R Ganguli
Journal:  Psychiatr Genet       Date:  1996       Impact factor: 2.458

Review 3.  Dissecting the genetic complexity of schizophrenia.

Authors:  M Karayiorgou; J A Gogos
Journal:  Mol Psychiatry       Date:  1997-05       Impact factor: 15.992

4.  A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization.

Authors:  N Ozaki; H Manji; V Lubierman; S J Lu; J Lappalainen; N E Rosenthal; D Goldman
Journal:  J Neurochem       Date:  1997-05       Impact factor: 5.372

5.  Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine.

Authors:  M J Arranz; J Munro; M J Owen; G Spurlock; P C Sham; J Zhao; G Kirov; D A Collier; R W Kerwin
Journal:  Mol Psychiatry       Date:  1998-01       Impact factor: 15.992

6.  Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia.

Authors:  Y Inayama; H Yoneda; T Sakai; T Ishida; Y Nonomura; Y Kono; R Takahata; J Koh; J Sakai; A Takai; Y Inada; H Asaba
Journal:  Am J Med Genet       Date:  1996-02-16

7.  Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine.

Authors:  A K Malhotra; D Goldman; N Ozaki; A Breier; R Buchanan; D Pickar
Journal:  Am J Psychiatry       Date:  1996-08       Impact factor: 18.112

8.  Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients.

Authors:  E J Bartlett; J D Brodie; P Simkowitz; R Schlösser; S L Dewey; J P Lindenmayer; H Rusinek; A Wolkin; R Cancro; W Schiffer
Journal:  Am J Psychiatry       Date:  1998-03       Impact factor: 18.112

9.  A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter.

Authors:  G Spurlock; A Heils; P Holmans; J Williams; U M D'Souza; A Cardno; K C Murphy; L Jones; P R Buckland; P McGuffin; K P Lesch; M J Owen
Journal:  Mol Psychiatry       Date:  1998-01       Impact factor: 15.992

10.  Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia.

Authors:  J Williams; P McGuffin; M Nöthen; M J Owen
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

View more
  21 in total

Review 1.  Genetic variations in human G protein-coupled receptors: implications for drug therapy.

Authors:  W Sadee; E Hoeg; J Lucas; D Wang
Journal:  AAPS PharmSci       Date:  2001

Review 2.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

Review 3.  Understanding putative risk factors for schizophrenia: retrospective and prospective studies.

Authors:  Suzanne King; David Laplante; Ridha Joober
Journal:  J Psychiatry Neurosci       Date:  2005-09       Impact factor: 6.186

4.  Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.

Authors:  Anna C Need; Richard S E Keefe; Dongliang Ge; Iris Grossman; Sam Dickson; Joseph P McEvoy; David B Goldstein
Journal:  Eur J Hum Genet       Date:  2009-01-21       Impact factor: 4.246

Review 5.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 6.  Pharmacogenomics in psychiatry: the relevance of receptor and transporter polymorphisms.

Authors:  Gavin P Reynolds; Olga O McGowan; Caroline F Dalton
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 7.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

8.  Differential effects of 5-HT(2A) and 5-HT(2C) receptor blockade on strategy-switching.

Authors:  Phillip M Baker; Jennifer L Thompson; John A Sweeney; Michael E Ragozzino
Journal:  Behav Brain Res       Date:  2011-01-12       Impact factor: 3.332

Review 9.  Pharmacogenetics as a tool in the therapy of schizophrenia.

Authors:  Bob Wilffert; Rianne Zaal; Jacobus R B J Brouwers
Journal:  Pharm World Sci       Date:  2005-02

Review 10.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.